ArticleCirculation2021

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.

Stefan D Anker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.